These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35770616)

  • 1. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
    Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
    Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
    Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
    Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Castleman disease.
    Dispenzieri A; Fajgenbaum DC
    Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
    Lurain K; Yarchoan R; Uldrick TS
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):75-88. PubMed ID: 29157621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.
    Pria AD; Pinato D; Roe J; Naresh K; Nelson M; Bower M
    Blood; 2017 Apr; 129(15):2143-2147. PubMed ID: 28143881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
    Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
    Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
    Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
    Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
    Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
    Milota T; Střížová Z; Sobotková M; Bartůňková J
    Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
    Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
    Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
    Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
    Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.
    Ramaswami R; Lurain K; Polizzotto MN; Ekwede I; Waldon K; Steinberg SM; Mangusan R; Widell A; Rupert A; George J; Gonçalves PH; Marshall VA; Whitby D; Wang HW; Pittaluga S; Jaffe ES; Little RF; Uldrick TS; Yarchoan R
    Blood Adv; 2021 Mar; 5(6):1660-1670. PubMed ID: 33720337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.